Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 2Thoracic 1Gynecologic 1Genitourinary 1CNS 1Breast 1

Conditions

Breast Neoplasms 5Brain Neoplasms 5Glioblastoma 3Carcinoma, Non-Small-Cell Lung 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Small Cell Lung Carcinoma 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Meningeal Carcinomatosis 1Esophageal Neoplasms 1Endometrial Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Ovarian Epithelial 1Carcinoma, Hepatocellular 1

Interventions

Gemcitabine 5Temozolomide 3Paclitaxel 3Oxaliplatin 3Nivolumab 3Leucovorin 3Irinotecan 3Erlotinib Hydrochloride 3Bevacizumab 3ulixertinib 2tovorafenib 2pembrolizumab 2Trastuzumab 2Specimen Handling 2Radiotherapy 2Magnetic Resonance Spectroscopy 2Fluorouracil 2Fluorodeoxyglucose F18 2Docetaxel 2Cyclophosphamide 2Cetuximab 2Carboplatin 2vocimagene amiretrorepvec 1trastuzumab deruxtecan 1trastuzumab biosimilar HLX02 1trametinib 1tipifarnib 1temsirolimus 1spartalizumab 1sargramostim 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pancreatic Neoplasms × sacituzumab govitecan × CNS × Clear all
NCT01631552 2021-08-12

Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer

Gilead Sciences

Phase 1/2 Completed
515 enrolled 28 charts 1 FDA
BreastCNSGastrointestinalGenitourinaryGynecologicThoracic

Carcinoma, Ovarian Epithelial, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Glioblastoma, Carcinoma, Hepatocellular, Pancreatic Neoplasms, Endometrial Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡